Santen Pharmaceutical (OTCMKTS:SNPHY) Reaches New 1-Year High – Here’s What Happened
by Tristan Rich · The Markets DailySanten Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $13.10 and last traded at $13.10, with a volume of 718 shares trading hands. The stock had previously closed at $12.31.
Analysts Set New Price Targets
Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has an average rating of “Hold”.
Read Our Latest Research Report on SNPHY
Santen Pharmaceutical Trading Up 6.0%
The firm has a market capitalization of $4.22 billion and a P/E ratio of 0.10. The business’s fifty day moving average is $11.50 and its 200 day moving average is $11.10.
Santen Pharmaceutical Company Profile
Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.
With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.